FGFR1 and thyroid gland carcinoma: In addition, the activity of lenvatinib through the inhibition of multiple RTKs may contribute to its antitumor activity against thyroid cancer cell lines with gene alterations (e.g., mutations or rearrangements) and overexpression of targeted RTKs, such as RET and FGFR1.